Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City

PALO ALTO, Calif., May 4, 2017 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, will host a key opinion leader lunch to address the need for novel mechanisms in the treatment of pulmonary arterial hypertension (PAH), promising preclinical research identifying the potential for disease modification in PAH, and new classes of investigational therapies now in the clinic.  The event will be held at the Lotte New York Palace Hotel in New York City on Wednesday, May 10th from 12:00pm to 1:30pm Eastern Time.